Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non‑small cell lung carcinoma: A case report and literature review

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.0, cancer incidence and mortality Worldwide: IARC CancerBase No. 11 [Internet]International agency for research on cancer. Lyon: 2013, http://globocan.iarc.frMarch 21–2018

Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI

Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, et al: Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27 Suppl 5:v1–v27. 2016. View Article : Google Scholar : PubMed/NCBI

Sakhri L, Meynet E, Ferrer L, Pirvu A, Ferretti G and Moro-Sibilot D: Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: A case report. J Med Case Rep. 8:3352014. View Article : Google Scholar : PubMed/NCBI

Ryu YJ, Chun EM, Lee SN and Shim SS: Progressive multiple cystic changes in both lungs in a patient treated with gefitinib for lung adenocarcinoma with multiple lung metastases. Korean J Radiol. 15:300–304. 2014. View Article : Google Scholar : PubMed/NCBI

Baybutt RC, Smith BW, Donskaya EV, Hu L, Li T and Wang W: The proliferative effects of retinoic acid on primary cultures of adult rat type II pneumocytes depend upon cell density. In Vitro Cell Dev Biol Anim. 46:20–27. 2010. View Article : Google Scholar : PubMed/NCBI

Higenbottam T, Kuwano K, Nemery B and Fujita Y: Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer. 91 Suppl 2:S31–S37. 2004. View Article : Google Scholar : PubMed/NCBI

Shepherd FA, Pereira Rodrigues J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI

Lind JS, Smit EF, Grünberg K, Senan S and Lagerwaard FJ: Fatal Interstitial lung disease after erlotinib for non-small cell lung cancer. J Thorac Oncol. 3:1050–1053. 2008. View Article : Google Scholar : PubMed/NCBI

Vahid B and Esmaili A: Erlotinib-associated acute pneumonitis: Report of two cases. Can Respir J. 14:167–170. 2007. View Article : Google Scholar : PubMed/NCBI

Chou CL, Ko HW, Wang CW, Yu CT, Kuo HP and Huang CD: Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma. Chang Gung Med J. 33:100–105. 2010.PubMed/NCBI

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI

Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and Benjamin RS: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol. 25:1753–1759. 2007. View Article : Google Scholar : PubMed/NCBI

Lee HY, Lee KS, Ahn MJ, Hwang HS, Lee JW, Park K, Ahn JS, Kim TS, Yi CA and Chung MJ: New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer. 73:63–69. 2011. View Article : Google Scholar : PubMed/NCBI